个 人 简 历
姓名:邓琦
职称:正高
导师类型:硕士研究生导师
教育经历
2003年9月~2006年7月 天津医科大学 分子生物学专业 硕士
1990年9月~1995年7月 天津医科大学医学系 学士
工作经历
2020年8月~今 天津市第一中心医院血液科 行政副主任
2011年11月~今 天津市第一中心医院血液科 主任医师
2006年11月~2011年10月 天津市第一中心医院血液科 副主任医师
2001年9月~2006年10月 天津市第一中心医院血液科 主治医师
1995年8月~2001年8月天津市第一中心医院血液科 住院医师
研究方向
血液系统疾病诊断治疗;血液系统恶性肿瘤细胞免疫治疗;恶性淋巴瘤基础研究
学术兼职
中国抗癌协会血液肿瘤专委会 委员;
中国医药生物技术协会医药生物技术临床应用专业委员会 常委;
中国医院协会血液学分会 委员;
中国免疫生物技术学会 委员;
天津医师协会血液科医师分会 常委;
天津市医疗健康学会 常委;
天津市整合医学淋巴瘤专委会 常委;
中国中西医结合天津血液学分会 常委;
天津市医疗健康学会精准检测委员会 常委;
中国抗癌协会血液肿瘤专委会 委员;
天津医学会血液学分会 委员;
中国抗癌协会天津分会 委员;
中国医药教育协会感染疾病专业委员会 委员;
天津市病案质控中心 副主任委员;
天津市血液病医疗质控中心 委员
代表性学术论文(近三年、通讯作者、SCI及中华杂志)
1 Guoling Wang, Xiaolei Sun, Shiyu Zuo, Chuo Li, Qing Niu, Yonghui Xia, Yuan Meng, Min Liu,Zihao Fang, Xi Yang, Yanyu Jiang, Sheng Wang, Haidong Cui, Huifang Huang, ErlieJiang, Dongming Zhou, Qi Deng*, Jing Pan* and Xiaoming Feng*. Homogeneously high expression of CD32b makes it a potential target for CAR T therapy for chronic lymphocytic leukemia. J Hematol Oncol (2021) 14:149.(通讯作者)
2 Jia Wang, Nan Mou, Zhenxing Yang, Qing Li, Yanyu Jiang, Juanxia Meng, Xuxiang Liu, Qi Deng*. Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukemia. British Journal of Haematology, 2020,191,212-222. doi: 10.1111/bjh.16623.(通讯作者)
3 Meijing Liu, Xuelin Wang, Zheng LI, Rui Zhang, Juan Mu, Yanyu Jiang, and Qi Deng*, LeiSun*. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. Cancer science,2020,111(11):4051-4060. PMID:32876369 DOI:10.1111/cas.14638(通讯作者)
4 Meijing Liu, Haobin Deng, Juan Mu2, Qing Li, Yedi Pu, Yili Jiang, Qi Deng*, Zhengzi Qian*. Ibrutinib improves the efficacy of anti-CD19-CAR T cell therapy in patients with refractory non-Hodgkin's lymphoma. Cancer science,2021 Jul;112(7):2642-2651. DOI: 10.1111/cas.14915(通讯作者)
5 Haobin Deng, Meijing Liu, Ting Yuan, Huan Zhang, Rui Cui, Jingyi Li, Jijun Yuan,Xiaofang Wang, Yafei Wang and Qi Deng*. Efficacy of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease. Frontiers in Immunology, 2021; 12: 720571.(通讯作者)(IF=7.561)
6 Rui Cui, Cuicui Lyu, Qing Li, Yanyu Jiang, Nan Mou, Zhenxing Yang, Xuxiang Liu, Deng Qi*, Lanfang Li*.Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematological oncology,2020,Sep 19,doi: 10.1002/hon.2807(通讯作者)
7 Wei Li, Meijing Liu, Ting Yuan, Lixiang Yan, Rui Cui, Qi Deng*. Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease. Hematological oncology,2022;1-10.(通讯作者)
8 Juan Mu, Haobin Deng, Cuicui Lyu, Jijun Yuan, Qing Li, Jia Wang, Yanyu Jiang, Qi Deng*, Jichun Shen*. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-CAR T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumour burden. Hematological oncology,2022 Feb 23. doi: 10.1002/hon.2981.(通讯作者)
9 Cuicui Lyu, Rui Cui, Jia Wang, Nan Mou, Yanyu Jiang, Wei Li* andQi Deng*.Intensive debulking chemotherapy improves the short-term and long-term efficacy of anti-CD19-CAR-T in refractory/relapsed DLBCL with high tumor bulk. Front Oncol.2021,Jul,30;11:706087.doi: 10.3389/fonc.2021.706087.(通讯作者)
10 Gang Feng, Qing Li, Haibo Zhu, Yanyu Jiang, Jijun Yuan, Yingxin Fu, and Qi Deng*. Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review. Front Oncol.2021 Sep 16;11:726134. doi: 10.3389/fonc.2021.726134.(通讯作者)
11 Pengjiang Liu, Meijing Liu, Cuicui Lyu, Wenyi Lu, Rui Cui, Jia Wang, Qing Li, Nan Mou, Qi Deng*, Donglin Yang*. Acute graft-versus-host disease post humanized anti-CD19-CAR T therapy for relapsed B-ALL patients after allogeneic hematopoietic stem cell transplant. Frontiers in oncology, 2020 Sep 29;10:573822. doi: 10.3389/fonc.2020.573822. (通讯作者)
12 Keke Deng, Wei Jiang, Yanyu Jiang, Qi Deng3*, Jinzhong Cao, Wenjie Yang*, Xuequn Zhao*. ALS3 Expression as an Indicator for Candida albicans Biofilm Formation and Drug Resistance. Frontiers in Microbiology, doi: 10.3389/fmicb.2021.655242. (通讯作者)
13 Xin Li, Haibo Zhu, Tao Sui, Xingli Zhao, Qi Deng. A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient. Cell Transplantation, 2022,31:9636897221132502. (通讯作者)(IF=4.139).
14Haibo Zhu, Qing Li, Yunyang Liu, Xuequan Feng, Qi Deng. A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient with Acute Lymphoblastic Leukemia. Cell Transplantation, 2022,31: 1-7.(通讯作者)
15 Qing Li, Cuicui Lyu, Meijing Liu, Jia Wang, Nan Mou, Erlie Jiang, Rongli Zhang, and Qi Deng. Donor Hematopoietic Stem Cell/ Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant. Cell Transplantation, 2023,32: 9636897231158155.(通讯作者)
16Xiupeng Ye,Xuemei Fan,Rui Cui,Juan Mu,Meijing Liu,Cuicui Lyu,Yeqiong Li,Lan Chen,Jin Zhang,Xin Li,Jia Wang,Nan Mou,Qi Deng. Efficacy and safety related factors of BTK inhibitors as a bridge to CAR T therapy in R/R FL. Annals of Hematology, 2023 May 12.doi: 10.1007/s00277-023-05255-w. (通讯作者)
17Yao Qi, Hong Liu, Xin Li, Yin Shi, Juan Mu, Jingyi Li, Ying Wang*, Qi Deng*. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy. Annals of Medicine,2023; 55(1): 2230888. (通讯作者)
18 Yi Li Jiang, Juan Mu, Rui Cui, Xin Li, Jia Wang, Qing Li, Jingyi Li, Nan Mou, Qi Deng*. Efficacy and side effects of anti- CD19 CAR T- cell therapy in patients with relapsed/refractory gastrointestinal lymphoma. Cancer Med. 2024 Feb;13(4): e7064. doi: 10.1002/cam4.7064. (通讯作者)
19 Jingyi Li, Juan Mu, Jia Wang, Xin Li, Qing Li, Yili Jiang, Qi Deng*. Persistent cytopenia after CD19 CAR T therapy in relapsed/refractory DLBCL patients could be a predictor of efficacy and side effects. Cell Transplantation, 2024 : 33:9636897241247951. doi: 10.1177/09636897241247951.(通讯作者)
20 Huan Zhang, Man Liu, Qing Li, Cuicui Lyu, Yan-Yu Jiang, Juan-Xia Meng, Jing-Yi Li & Qi Deng*. Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system. Leukemia & Lymphoma,2021 Sep 29;1-9.(通讯作者)
21 XIN LI, MEI-JING LIU, NAN MOU, ZHEN-XING YANG, JIA WANG, JUAN MU, HAI-BO ZHU, QI DENG*. Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T: A case report. Oncology Letters,2020(通讯作者)
22 Rui Zhang, Cuicui Lyu, Wenyi Lu, Yedi Pu, Yanyu Jiang, Qi Deng*. Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo. Am J Cancer Res, 2020;10(9):2800-2812.(通讯作者)
23 Yi-li Jiang, Qing Li, Ting Yuan, Yan-yu Jiang, Qi Deng*. Case report of anti-CD123-CAR T-cell therapy followed by radiotherapy for a recurrence blastic plasmacytoid dendritic cell neoplasm patient after allo-HSCT. OncoTargets and Therapy, 2020,13:3425-3430.(通讯作者)
24 Li Qing, Mu Juan, Yuan Ji-jun, Yang Zhen-xing, Wang Jia, Deng Qi*. Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant. OncoTargets and Therapy, 2020,13. 11471-11484.(通讯作者)
25 Haibo Zhu, Haobin Deng, Juan Mu, Cuicui Lyu, Yanyu Jiang, Qi Deng*.Anti-CD22 CAR-T cell therapy as a salvage treatment in B cell malignancies refractory or relapsed after anti-CD19 CAR-T therapy. OncoTargets and Therapy, 2021 Jul 2;14:4023-4037. doi: 10.2147/OTT.S312904.(通讯作者)
26 Juan Mu, Meijing Liu, Jia Wang, Juanxia Meng, Rui Zhang, Yanyu Jiang, Qi Deng*. Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma. Adv Clin Exp Med. 2022 Mar;31(3):327-335.(通讯作者)
27Xiupeng Ye, Meijing Liu, Cuicui Lv, Yeqiong Li Lan Chen, Jin Zhang, Juan Mu, Qi Deng. Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo. Technology in Cancer Research & Treatment, 2022,21: 1-10. (通讯作者)
28张蕊,李新,李征,江嫣雨,马立,赵明峰,邓琦*. PD-1抑制剂提高化疗药物对Raji细胞株杀伤活性的实验研究.中华血液学杂志,2020,41(1):76-79. (通讯作者)
29王嘉,牟男,孟娟霞,李新,江嫣雨,袁婷,邓琦*. 人源化与鼠源CD19 CAR-T细胞对Nalm-6细胞及成瘤小鼠的杀伤活性比较. 中华肿瘤杂志,2021,43(8):827-832. (通讯作者)
30 邓昊彬,刘美静,江嫣雨,袁婷,张蕊,邓琦*. CD19嵌合抗原受体T细胞靶向B细胞肿瘤细胞株过程中糖皮质激素对其扩增影响的体外研究. 中华血液学杂志,2021,42(9): 747-751.(通讯作者)
31 崔蕊,李平,李青,穆娟,蒋怡丽,江嫣雨,邓琦*.人源化BCMA CAR-T细胞挽救治疗鼠源BCMA CAR-T细胞治疗后再进展的难治
多发性骨髓瘤二例.中华血液学杂志,2020,42(6):502-507.(通讯作者)
32张蕊,牟男,蒲业迪,李青,江嫣雨,袁婷,邓琦*.过表达NKG2D-CD3ζ的NY-ESO-1 TCR-T细胞对一例急性髓系白血病原代细胞的杀伤活性体外研究.中华血液学杂志,2020,41(11):946-950(通讯作者).
33刘美静,穆娟,袁婷,崔蕊,孟娟霞,江嫣雨,李玉明,邓琦*. 急性B淋巴细胞白血病自体CD19 CAR-T制备中CD19 CAR转入体系残留白血病细胞的的体外研究. 中华血液学杂志,2021,42(2): 140-145.(通讯作者)
34 李青,邓昊彬,刘美静,吕翠翠,朱海波,王嘉,蒋怡丽,蒲业迪,江嫣雨,李维,邓琦*. CD19嵌合抗原受体修饰 T细胞治疗高肿瘤负荷的复发/难治B细胞淋巴瘤局部反应与疗效分析. 中华血液学杂志,中华血液学杂志,2021,42(7): 570-576.(通讯作者).
35 高舒荃,穆娟,李新,王嘉,崔蕊,李静怡,隋涛,邓琦*.骨髓可溶性B细胞成熟抗原表达在多发性骨髓瘤患者中作为BCMACAR-T细胞疗效预测指标的研究. 中华血液学杂志,2024,45(4):378-382.(通讯作者)
主持在研课题:
1.外周血 eNAMPT 表达预测伊布替尼提高 CD19 CAR-T 细胞对复发/难治弥漫大 B 细胞淋巴瘤疗效的基础与临床研究。2022年希思科—药明巨诺血液肿瘤科研基金项目(Y-2022YMJN/MS-0001)。2023.01-2025.12, 第一申请人(经费30.0万元)。
2.NAMPT作为复发/难治B细胞淋巴瘤CAR-T疗效预测指标的基础及临床研究。天津市卫生健康委员会,重点项目(TJWJ2023ZD003),2023.07.01~2026.06.30,第一申请人(经费20.0万元)。
3. 奥布替尼下调Notch-RBP-J信号通路促进巨噬细胞M1极化而增强CAR-T细胞疗效的基础及临床研究。2022年希思科—诺诚健华血液肿瘤科研基金项目(Y-NCJH202201-0027)。2022.10-2025.03, 第一申请人(经费9.0万元)。
获奖情况:
1提高复发/难治B细胞淋巴瘤CAR-T细胞疗效与安全性体系建立。天津市科学技术进步奖三等奖,(2022JB-3-164-R1),2022年,第一完成人。
2改进后的DC-CIK细胞免疫疗法在治疗急性白血病中的研究及临床应用。天津市科学技术进步奖三等奖(2013JB-3-150-R3),2013年,第三完成人。
联系方式
联系邮箱:kachydeng@126.com
联系地址:天津市南开区复康路24号,13612055872